Ask Warren

JONBUR Research · Initiation

SOS Lab · 464080 · Medical & precision devices

SOS Lab: Small Revenue Base, Deep Losses and a Share Price Well Below Its 52-Week High

Why this report

Start of coverage: written when a reader opened this company and there was no report yet.

SOS Lab, a KOSDAQ-listed maker in the medical and precision devices sector, has a market value of ₩156.9B against trailing revenue of ₩5.0B and an operating loss of ₩18.2B. The shares closed at ₩8,710, down 14.4% over one year and well below the 52-week high of ₩28,700, while recent news centers on new lidar products and partnerships.

Written Oct 23, 2026 · Data as of Oct 22, 2026 · 0 views

This is not financial advice. The report does not recommend buying or selling anything.

XfWATGr/in@

Thesis

The data supports a picture of a young company that is growing revenue but is far from profitable. Revenue rose 23.3% in 2025 to ₩6.1B, yet the operating loss widened to ₩16.1B from ₩12.8B in 2024. Trailing revenue to H1 2026 is ₩5.0B, below the 2025 full-year figure, so the data does not show a continued revenue ramp.

What the data does not show: there is no profit-based multiple, no model estimate of value, and no guidance in the data. The market is valuing the company at 31.2 times sales and 10.6 times book value, so expectations for future growth appear to be built into the price. Recent product news and partnership headlines are visible, but the data does not quantify their revenue impact.

Business overview

SOS Lab is listed on KOSDAQ under code 464080 and is classified in medical and precision devices. It was founded on 2016-06-22 and listed on 2024-06-25, with 18,013,569 listed shares. The CEO is listed as 정지성. Market capitalization is ₩156.9B and enterprise value is ₩183.9B.

Revenue was ₩4.9B in 2024 and ₩6.1B in 2025. Recent news headlines describe a lidar product for smart infrastructure called ML-I shown at the ITS World Congress in Gangneung, a parking guidance solution, and a partnership to explore lidar and AI semiconductor convergence. Filings also list major sales or supply contracts on 2026-06-16 and 2026-09-01; contract sizes are not in the data.

Financial analysis

These figures come from filed financial statements. For the trailing twelve months to H1 2026, revenue was ₩5.0B, operating income was -₩18.2B and net income was -₩19.5B. Operating margin was -361.7% and net margin was -388.4%. Return on equity was -83.6%.

For 2025, revenue was ₩6.1B, operating income -₩16.1B (margin -265.1%) and net income -₩17.7B, with ROE of -60.6%. In 2024, operating income was -₩12.8B (margin -259.9%), net income -₩12.0B and ROE -37.4%. Losses have widened each year.

The balance sheet is stretched. Cash is ₩1.9B against borrowings of ₩49.9B, and liabilities are 391.8% of equity. Trailing free cash flow is -₩15.5B, so cash on hand covers a little over one month at that pace without new funding.

Valuation

Price-to-earnings and EV/EBITDA cannot be calculated because earnings are negative. Price-to-book is 10.6, up from 9.7 at the end of 2025 and 7.6 at the end of 2024. Price-to-sales is 31.2. The dividend yield is 0.0%.

Among the listed peers, price-to-book ranges from 3.2 (Kctech) to 21.1 (Curiox Biosystems, which also has no P/E). TSE trades at 5.9 times book, Classys at 3.4 and Park Systems at 5.1. SOS Lab's 10.6 is above most of these peers, though those peers have positive P/E ratios from 13.5 to 74.7 and are much larger, with market caps of ₩1.0T to ₩2.8T.

The valuation model estimate is not available for this company, so there is no model figure to compare with the share price of ₩8,710.

Catalysts

  • An adjustment of the conversion price was filed on 2026-10-12, which relates to convertible securities and could affect share count and dilution.
  • The ML-I infrastructure lidar was unveiled at the ITS World Congress in Gangneung in mid-October 2026, drawing several news reports.
  • A partnership with Semunite (reported as Cemunite by Edaily) was announced on 2026-10-13 to explore lidar and AI semiconductor convergence and autonomous driving business.
  • Major sales or supply contract filings on 2026-06-16 and 2026-09-01 show order activity, although amounts are not given in the data.
  • Foreign ownership rose to 2.1% from 1.2% sixty days ago, and institutions were net buyers of ₩1.0B over 20 days.

Risks

  • Operating losses have widened for two years and the trailing operating margin is -361.7%, so continued funding needs are likely.
  • Cash of ₩1.9B is small relative to borrowings of ₩49.9B and trailing free cash flow of -₩15.5B.
  • Liabilities are 391.8% of equity, and the conversion price adjustment points to convertible securities that may dilute shareholders.
  • The shares trade at 31.2 times sales and 10.6 times book value, so the price depends heavily on growth that the filed numbers do not yet show.
  • The share price is 69.7% below its 52-week high and fell 9.8% over the past month, indicating high volatility.

Closing view

The evidence shows a company with real but very small revenue, rising losses, thin cash and heavy debt, set against a market value that is large relative to sales. Product launches, partnerships and contract filings suggest commercial activity, yet the data gives no contract values and no profitability path. No model estimate is available, so the valuation cannot be checked against a fair-value range. The picture is one of high uncertainty in which financing and dilution matter as much as operating progress.

Model estimate of fair value

The valuation model has no estimate for this company yet (not enough data, or no positive value with the base case).

Filings and data used

Report history

  1. Oct 23, 2026InitiationStart of coverage (reader request)SOS Lab: Small Revenue Base, Deep Losses and a Share Price Well Below Its 52-Week High

Built only from jonbur's own data: prices and investor flows, filed financial statements and filings, and news headlines. Disclosed (filed) data is labelled as such. Written by AI and may contain mistakes.

This is not financial advice. The report does not recommend buying or selling anything.

Source: KRX statistical information